Understanding CIRS & the CIRS+ Patient

A terrain-first, root-cause guide to mold and biotoxin illness — why recovery is rarely just about mold, why the order of treatment matters more than almost anything, and how we help the most complex patients finally move forward.

After working with hundreds of patients, I can say with confidence that the CIRS protocol works. It is one of the most effective tools we have for lowering biotoxin burden and restoring quality of life. But the protocol is also nuanced — and a meaningful share of our patients stay exquisitely sensitive and complex because biotoxins are not the only thing taxing their immune system. This guide is about both halves of that truth, written for the patient who has read everything, tried much of it, and is still searching for the missing piece.

Chronic Inflammatory Response Syndrome — CIRS — is a multisystem, multi-symptom illness driven by ongoing innate-immune inflammation in genetically susceptible people who cannot clear certain biotoxins efficiently. The framework was built over more than two decades by Ritchie Shoemaker, MD, and expanded by clinicians and researchers including Andrew Heyman, MD, James Ryan, PhD, Scott McMahon, MD, and a growing community of others. It now rests on a real body of published, peer-reviewed work — including the transcriptomic (gene-expression) research that lets us see the illness at the level of differential gene activation instead of guessing from symptoms alone.

I want to be candid about two things up front. First, conventional medicine does not yet universally recognize CIRS as a discrete diagnosis, which is exactly why patients with very real, very disabling symptoms so often hear that “all your tests are normal.” Second, the science here is genuinely emerging and best applied by a clinician specifically trained in it. What follows is the model we use at Tree of Light Health — grounded in the published protocol, refined by experience with complex cases, and expanded into the territory we call CIRS+.

What CIRS actually is

In roughly three-quarters of people, biotoxins from a moldy building, a tick bite, or contaminated water are tagged by the immune system and cleared harmlessly through the liver and bile. But about a quarter of the population carries certain HLA-DR/DQ immune-response genes that impair antigen presentation. In these individuals the toxins are never properly “seen,” never cleared, and instead drive a self-perpetuating inflammatory cascade. As Shoemaker puts it, if the dysregulated gene transcription isn’t corrected, the patient isn’t corrected — this is a problem of immune signaling, not a simple allergy.

It’s worth being precise here, because the HLA story is often oversimplified. The genes appear to set a susceptibility — an inefficiency in how the immune system introduces certain microbial fragments to the rest of the system — rather than dictating exactly which illness, or how severe it will be. Plenty of people with a “mold-susceptible” type carry heavy burdens that look nothing like a textbook case. The gene is a risk factor that needs other conditions in place to fully express.

The biotoxin pathway, in plain terms

Once inflammation switches on and fails to switch off, a predictable chain of events unfolds. Biotoxins act directly on nerve cells (detectable early through the Visual Contrast Sensitivity test) and bind receptors on fat cells, triggering a flood of inflammatory cytokines. Those cytokines:

• restrict capillary blood flow, lowering tissue oxygen and eventually suppressing VEGF — producing fatigue, air hunger, muscle cramping, and poor exercise recovery;
• drive up inflammatory markers such as MMP-9, TNF, IL-1β, and PAI-1;
• damage leptin receptors in the hypothalamus, which collapses production of MSH (melanocyte-stimulating hormone) — the master regulator whose loss disrupts sleep, pain control, gut integrity, and pituitary function;
• cascade downstream into ADH/osmolality dysregulation (thirst, frequent urination, static shocks), ACTH/cortisol swings, low sex hormones, and a leaky, gliadin-reactive gut.

MSH sits at the center of the whole picture. When it falls, the deep nasal passages lose a key protection and become hospitable to MARCoNS — multiply antibiotic-resistant staph that live inside a biofilm, cleave MSH still further, and feed the cycle. It is, quite literally, inflammation begetting inflammation. We’ll return to MARCoNS and the sinuses in detail, because in our experience that’s where many stalled cases are won or lost.

It was never “just mold”

This is one of the most important shifts in the field, and most patients have never heard it. Water-damaged buildings are the most common trigger in the United States, but the inside of a wet building is a microbial ecosystem, not a single villain. When we say “mold illness,” we’re really using shorthand for a whole stew of inflammatory agents. The major players:

• Mold & mycotoxins. The fungi everyone thinks of, and the toxic metabolites they excrete. Real, but — based on emerging gene-expression data discussed by CIRS researchers — often a smaller slice of the causation pie than the name “mold illness” implies.
• Actinobacteria (actinomycetes). Filamentous, slow-growing bacteria that thrive in chronically damp building materials and dust. They are now understood to be one of the most important and most common contributors to CIRS — and they barely register on the testing most people are sold. More on what these assays actually are below.
• Endotoxins (LPS). Fragments of the cell walls of gram-negative bacteria. Potent immune triggers in their own right, and — crucially — they can come from two completely different directions (explained below).
• Beta-glucans & fungal cell-wall fragments. Inflammatory even when the mold itself is dead. This is why “I killed the mold” doesn’t mean “the building is safe.”
• Microbial VOCs. The volatile organic compounds that produce that musty smell — themselves a source of symptoms for sensitive people.

What are Actinobacteria, really?

Think of Actinobacteria as the quiet, late-arriving troublemaker of biotoxin illness. Drawing on the work of Dr. Christian Navarro-Torres (CIRS Lab) and Dr. Shoemaker, our clinical view is that mold often acts as the primer — the initial hit that throws the immune system off — while Actinobacteria tend to creep in later, once the system is already exhausted and dysregulated. They aren’t usually the loud, inflammatory type of organism. They’re metabolic saboteurs. Patients with a heavy Actinobacteria load tend to describe a distinctive “zombification” — bone-deep fatigue, a frozen brain and body, the sense that the lights are on but the power is low. On advanced brain imaging this can correspond to what Shoemaker calls molecular hypometabolism, sometimes with shrinkage of a deep, metabolically sensitive brain region called the pallidum. When a patient has done everything “right” and still feels metabolically stuck, Actinobacteria is high on our list.

Endotoxins: is it coming from your sewer, or from your gut?

Endotoxin is one of the trickiest pieces of the puzzle, because the same inflammatory molecule can arrive from outside or from inside:

• External / environmental. Leaking or compromised sewer and drain lines, certain HVAC conditions, even a nearby water-treatment plant or a lake prone to cyanobacterial blooms. Some highly sensitive patients react to the vicinity of a home, not just the home itself.
• Internal / endogenous. A leaky gut. When the intestinal barrier is compromised, endotoxin from your own gram-negative gut bacteria can translocate into the bloodstream and drive the very same inflammation — a phenomenon increasingly recognized in the neurodegeneration literature.

This distinction is not academic. If we don’t figure out where the endotoxin is coming from, we can chase the wrong target for months. The deciding factor is often permeability: a person with strong gut, skin, and nasal barriers is far more resilient to endotoxin than someone whose barriers are breached.

The concurrent problems hiding inside a CIRS case

Here is something every complex patient needs to hear: many different conditions can elevate the same inflammatory labs, and many of them have nothing to do with mold. Sleep apnea, metabolic disorders, hidden parasites, chronic infections — all of these can push markers like MMP-9, TGF-β1, and others in the same direction mold does. That means a “CIRS-looking” lab panel is the beginning of the investigation, not the end of it. If we only treat the mold and ignore an undiagnosed sleep apnea or a parasite burden, the labs never fully normalize and the patient never fully recovers. Several layers deserve special attention.

Mast cell activation (MCAS) & histamine overload

Mold, Lyme, and chronic inflammation are classic mast-cell triggers, and dysregulated mast cells make patients react to foods, smells, supplements, and even the treatments meant to help them. Many of our most sensitive patients are not “difficult” — they’re histamine-overloaded, and until we calm the mast cells, almost nothing else is tolerated. Interestingly, MSH and MMP-9 both appear to track with histamine reactivity, which is part of why stabilizing this layer early can unlock progress everywhere else. We go deep on this in our companion article on Mast Cell Activation Syndrome.

SIBO, leaky gut & the gut–sinus–brain axis

Gut dysfunction is nearly universal in serious CIRS. Low MSH alone damages gut integrity, and where we see high Actinobacteria and low MSH in the sinuses, we almost always find work to do in the gut: SIBO/SIFO, food intolerances, histamine issues, and the leaky-gut endotoxin problem described above. The gut, the sinuses, and the brain are wired together through immune and neuroendocrine signaling — improving one often improves the others. In our experience, addressing the sinuses first and then working downward into the gut tends to be the more forgiving order for sensitive patients.

The “priming event” model

A useful way to hold all of this: some exposures prime the illness (mold’s ribotoxins are uniquely capable of disrupting ancient RNA machinery and setting the stage), while other burdens drive its persistence once it’s switched on (Actinobacteria, endotoxin amplification, chronic infections, parasites). The priming event may be long gone; what keeps a person sick is the layered burden that moved in afterward. This is why “I already left the moldy house — why am I still sick?” is such a common and important question, and why the answer is so often found in these hidden layers.

Why the order of treatment matters more than almost anything

If you take one practical thing from this entire guide, take this: in CIRS, doing the right things in the wrong order is one of the fastest ways to get worse. The protocol is sequential by design. Each step corrects an upstream problem so the next step can succeed, and many later markers normalize on their own once the earlier work is done. Skip ahead, and you can flare hard, lose trust in the process, and conclude (wrongly) that “nothing works.”

MARCoNS & the sinus biome — the battle that decides the war

Of all the steps in the protocol, the sinuses may be the most underestimated. In our clinical experience — and echoing what researchers like Navarro-Torres now argue — the sinuses are arguably the most privileged and important real estate in a CIRS patient. They sit close to the brain’s regulatory centers, and what happens in that small, immune-tolerant space appears to ripple outward into the neuroendocrine signaling that drives the whole multi-system illness. Win the sinus battle, and you often start regaining control over everything else.

Why MARCoNS has gotten harder to clear

The classic Shoemaker-era treatment was a compounded BEG nasal spray (Bactroban, EDTA, gentamicin). It still has a role, but two things have changed. First, MARCoNS has grown increasingly resistant, and BEG simply fails more often than it used to. Second, BEG can provoke a harsh “herx” — worsening brain fog and fatigue as the bugs die off — especially in someone still getting ongoing exposure. So our approach has evolved.

A gentler, often more effective approach

For many patients we now favor a combination built around a xylitol nasal spray (Xlear) plus EDTA (to break up the protective biofilm) and, frequently, colloidal silver, used twice daily over roughly six weeks or longer depending on response. In-vitro studies from independent microbiology laboratories have shown that ionic/colloidal silver can eradicate MARCoNS — including stubborn biofilm-positive strains — along with a broad range of gram-positive and gram-negative bacteria, yeast, and mold, and that EDTA meaningfully disrupts the biofilm that shields these organisms. Certain botanical and essential-oil agents (witch hazel, oregano, curcumin, artemisinin and others) have shown inhibitory activity as well. We individualize the exact combination to the patient.

When the sinuses are stubborn: advanced biome testing

A standard MARCoNS culture only answers one narrow question: is multi-resistant staph present, yes or no? But the nasal biome is far richer than that, and in our hardest cases a single staph result misses the real story. For these patients we turn to advanced sinus-biome (sinubiome) testing — DNA-based panels such as the MicroGenDX SinusKEY — which speciate the entire nasal ecosystem: fungi, gram-positive and gram-negative bacteria, and, importantly, Actinobacteria such as C. acnes and Corynebacterium species. This is where the “stalled” patient — low MSH, persistent fatigue, no response to standard care — often finally reveals what’s actually going on. When fungal colonization shows up, high Actinobacteria activity tends to ride along with it, and the strategy shifts from “kill the staph” to “rebalance the whole ecosystem” (addressing pH, lipid-rich hiding places, and biofilm, sometimes with botanicals like Horopito/Kolorex rather than antibiotics alone).

Seeing the disease clearly: biomarkers, NeuroQuant & GENIE

A proper CIRS evaluation braids together history, a symptom-cluster analysis, the VCS screen, blood biomarkers, and — in the right cases — advanced imaging and genomics. No single test makes the diagnosis; the pattern does. A few of the tools we lean on:

• Exposure history & environmental testing — ERMI/HERTSMI-2 for buildings (a HERTSMI-2 score under 11 is generally considered safe for re-entry, with sensitive patients needing lower).
• Visual Contrast Sensitivity (VCS) — an inexpensive, repeatable neurologic screen that tracks treatment response over time.
• Genetic susceptibility — HLA-DR/DQ haplotype testing.
• Inflammatory & hormonal biomarkers — C4a, C3a, TGF-β1, MMP-9, MSH, VEGF, VIP, ADH/osmolality, ACTH/cortisol, leptin, anti-gliadin and anti-cardiolipin antibodies, and a MARCoNS nasal culture.

A few honest caveats on the classics: C4a has become hard to run reliably outside the National Jewish lab, so we weight it less than we used to. TGF-β1 shifted upward across the population during the COVID era, so we pay attention mainly when it’s clearly extreme — a value above 10,000 is hard to dismiss as noise. No single marker proves causation; the pattern, read in the context of the whole person, is what matters.

NeuroQuant: reading the brain

NeuroQuant is volumetric MRI analysis — software that measures the size of specific brain structures and compares them to healthy people of the same age and sex. In CIRS we use it for several things at once. Early in the illness — what some call “brain on fire” — we often see enlarged white-matter tracts, plausibly reflecting activated microglia (the brain’s own innate immune cells). Later, or in more depleted patients, we may see atrophy: the pallidum (that metabolically sensitive region tied to Actinobacteria and molecular hypometabolism), cortical gray matter, and limbic structures. The high-resolution atrophy report can also surface an old traumatic brain injury, and certain white-matter patterns can raise suspicion for vascular stress from Bartonella. It’s not a stand-alone diagnosis — but combined with labs and history, it sharply raises our confidence about what is driving a given brain.

GENIE: reverse transcriptomics, or “what is actually causing the inflammation?”

This is the development that has changed the field. For decades we inferred the cause of inflammation from symptoms and a handful of proteins. GENIE and related transcriptomic tools instead read gene expression — which of your genes are switched on and off right now — and match those patterns to known signatures. Practically, this lets us begin to differentiate drivers that look identical on a symptom checklist:

• Mold / mycotoxin inflammation.
• Lyme versus post-Lyme patterns.
• Endotoxin activity (e.g., CD14 and toll-receptor signatures).
• Actinobacteria burden (often seen with up-regulated MAP-kinase and TGF-β1 receptor pathways), and
• an excess-histamine / mast-cell pattern and the cellular-hypometabolism “cell danger” state.

Emerging GENIE data discussed by CIRS researchers have been eye-opening about proportions — suggesting Actinobacteria and endotoxin together account for a far larger share of causation than mold and mycotoxins alone, even though mold often remains the original primer. We treat these figures as evolving rather than final, and we never read GENIE in isolation: it’s most powerful alongside NeuroQuant, blood work, VCS, symptom history, and the patient’s living situation. But for the complex patient, the ability to tell mold-driven from Lyme-driven from endotoxin-driven from Actinobacteria-driven inflammation — instead of guessing — is genuinely transformative.

The Shoemaker protocol — the foundation we build on

The protocol is sequential by design, and a 2025 peer-reviewed review in Medical Research Archives reaffirmed it as a structured, evidence-based approach. Used faithfully, it reliably lowers biotoxin burden and improves symptoms. We think of it as the foundational entry point — the framework that has to be in place before the deeper, more individualized work on complex patients can succeed. The arc, in brief:

1. Remove the exposure. The single most important step. Confirm a safe environment before pushing forward — everything downstream depends on it.
2. Bind & remove toxins. Cholestyramine is by far the most powerful binder for mold-related biotoxins; we often round it out with natural binders to broaden the effect. The gentler Welchol (colesevelam) is frequently the better-tolerated choice — long thought weaker, but in practice it moves the needle with far fewer side effects, which is why much of the field now reaches for it first.
3. Address the sinuses / MARCoNS. Deep nasal culture, then targeted antibiofilm/antimicrobial therapy — because resident MARCoNS keep MSH suppressed and blunt the response to everything else.
4. Address gluten & gut. Strict gluten elimination in anti-gliadin–positive patients, with celiac ruled out, plus the broader gut work.
5. Correct ADH / osmolality. Desmopressin (DDAVP) where warranted, with close sodium and electrolyte monitoring — this is what calms the relentless thirst, frequent urination, and static shocks.
6. Correct MMP-9 & VEGF. A low-amylose diet plus high-dose omega-3s, with targeted agents in select cases.
7. Resolve C3a & C4a. Persistent C3a points to ongoing microbial membranes (often tick-borne); C4a tends to settle as earlier steps succeed and exposure is controlled.
8. Lower TGF-β1. Losartan and/or VIP, antioxidants, and lifestyle support to calm the Th17 / fibrosis arm.
9. Restore VIP. Intranasal VIP — the final step — re-regulates immune, vascular, and hormonal systems, helps restore grey-matter volume, and protects against re-exposure flares. Used only once ERMI/HERTSMI-2, VCS, MARCoNS, and MMP-9 criteria are met.

This backbone is real, and it is effective. The honest clinical reality is simply that not every patient sails through it — which brings us to the harder, more interesting half of the conversation.

Why the protocol isn’t always enough

Some patients improve steadily and beautifully. Others can barely tolerate a half-scoop of binder before they flare — headaches, air hunger, mood crashes, full-body reactivity. When that happens, it almost never means the protocol is wrong. It usually means the terrain isn’t ready, or the patient is carrying more than biotoxins. A few recurring blocks explain most of the difficulty.

Closed drainage pathways

Binders mobilize toxins, but the body still has to excrete them — through stool, bile, urine, lymph, sweat, and breath. If those drainage routes are sluggish, mobilized toxins simply recirculate and the patient feels poisoned. Opening drainage before aggressive binding — bowel regularity, bile flow, lymphatic movement, hydration and minerals, gentle sweating — is one of the most reliable ways to make the protocol tolerable.

Mast cells & histamine (again)

The MCAS layer from Part III shows up here as a tolerance problem: when mast cells are unstable, patients react to the very binders and antimicrobials meant to help. Stabilizing them first is often what finally lets treatment proceed.

A nervous system stuck in alarm — often where we start

Chronic biotoxin illness keeps the autonomic nervous system locked in fight-or-flight — the cellular-danger, hypometabolic state GENIE now helps identify. In that mode, detoxification, repair, and immune regulation all suffer, and the brain’s limbic “threat” circuitry amplifies every sensation into a flare. Here is the part that gets missed: nervous-system regulation is critical, and the Shoemaker protocol does not directly address it. For a great many of our patients, calming the system isn’t a finishing touch — it’s the first thing we do, because nothing else is tolerated until the body stops bracing for impact.

The tool we lean on most heavily here is IASIS microcurrent neurofeedback — a gentle, non-invasive therapy that uses ultra-low microcurrents to help the brain release stuck, dysregulated patterns and shift out of survival mode. For our most sensitive patients, IASIS is frequently where we begin: it acts like a soil conditioner, making the whole system more receptive so that detox, antimicrobial, and immune work can actually land. Patients who could tolerate almost nothing often find that after IASIS, the door finally opens. We pair it with active nervous-system retraining programs — Primal Trust and DNRS (Dynamic Neural Retraining System) — along with breathwork, vagal toning, and neural therapy. None of this is a soft add-on; for the sensitive patient it is routinely the rate-limiting step in the entire recovery.

The hypersensitive patient & microdosing

For the truly sensitive — the people who react to opening a supplement bottle — the answer is rarely “push harder.” It’s to start absurdly low and climb slowly: crushing and diluting a binder to a fraction of a dose, learning to read which reactions signal genuine progress versus pure intolerance, and giving the body time between steps. It can take weeks to reach a dose another patient starts at. That patience isn’t weakness in the plan; it is the plan.

When biotoxins aren’t the only threat

This is the heart of what we see every week. A large share of our most complex patients are not “CIRS” so much as CIRS+ — biotoxin illness layered on top of one or more additional, immune-taxing burdens. Each can mimic CIRS, amplify it, and stall recovery if it goes unaddressed. The idea isn’t original to us — it echoes Dr. Richard Horowitz’s 16-point MSIDS model of overlapping infectious and inflammatory drivers — but in the mold-illness population it is the rule, not the exception. The most common additional threats we look for:

Add to this the supporting cast that shapes the terrain: gut dysbiosis, SIBO/SIFO and yeast overgrowth, heavy metals, hypercoagulation/microclotting, and ongoing environmental sensitivity. None of these exists in isolation — they form a web, which is exactly why treating a CIRS+ patient as if they had a single problem so often disappoints. But two of these threads deserve a much harder look, because in our experience they are the most consistently missed.

The parasite factor — the missing piece in the hardest cases

We’ll say this plainly, because most patients have never been told it: in our most complex, hypersensitive CIRS patients, a heavy parasite burden is very often the missing factor — and clearing it, in the right order, is where the biggest breakthroughs happen. This is controversial in some circles, and we hold it as a strong clinical conviction rather than settled fact. But it lines up with what leading CIRS researchers like Dr. Christian Navarro-Torres now describe from their own recoveries: that the sickest, most reactive patients tend to be carrying a large, under-recognized parasitic load.

Parasites behave like the great enablers of chronic illness. Once they establish themselves, they drag everything else downstream with them. They shift and confuse the immune system, steering it toward a reactive, allergic posture that keeps mast cells, histamine, and inflammation lit up. They can open the door for other organisms — even helping entrench the Actinobacteria and co-infections we discussed earlier. They can distort the very markers we test, including patterns on advanced genomic (GENIE) testing — so they muddy the picture while hiding in plain sight. And they are notoriously hard to detect: standard stool and serology testing produces frequent false negatives, which is exactly why so many patients are told they’re “clear” when they are not.

Because the labs are so unreliable, we lean heavily on symptom pattern and on Autonomic Response Testing (ART) to decide whether parasites are present and — just as importantly — when in the sequence to treat them. And sequence is the whole game here. Treat parasites too early — before the environment, drainage, sinuses, and nervous system are ready — and you can trigger a punishing flare. Treat them in the right order, after the foundation is laid, and patients who were stuck for years often describe a genuine turning point. Our approach typically layers gentle botanical antiparasitics (the classic black walnut, wormwood, and clove family) first, and, when the burden is heavy enough and the patient is ready, carefully supervised, pulsed courses of pharmaceutical antiparasitics such as ivermectin with albendazole or mebendazole. We detail the pharmaceutical options by parasite type in our companion article on antiparasitic medications — but the medication is never the point. The right target, in the right order, identified with ART — that’s the principle.

Spike protein — the newest X-factor

Since 2020 we’ve seen another driver enter the CIRS picture that simply wasn’t on the map before: persistent spike protein, whether from COVID infection or, in some patients, after vaccination. We increasingly think of spike as an X-factor that can prime or amplify CIRS — adding inflammatory, vascular, and neurologic stress, and helping reactivate latent burdens like EBV, Bartonella, and Mycoplasma by further dysregulating an already-confused immune system. For the patient whose illness clearly turned a corner “after COVID” (or who “got over COVID but never came back”), this layer needs its own strategy. We go deep on it in our article on when the spike protein won’t let go.

Your home is usually the bottleneck

Here is the truth we come back to with almost every patient: you cannot out-supplement a sick building. CIRS recovery can take many months, and sometimes years — and the single biggest reason it stretches that long is an environment the patient can’t get out of, or can’t get truly clean. Get the environment right and everything else accelerates. Leave it unresolved and even the best protocol stalls.

“Don’t all homes have mold?”

We hear this constantly, and the answer is: in a sense, yes. Mold spores exist almost everywhere. What separates a benign home from a sickening one isn’t the mere presence of mold — it’s the concentration of problem species, the duration of exposure, and the accompanying load of VOCs, endotoxins, and Actinobacteria. A trace of outdoor mold tracked in on shoes is not the same as a chronically damp wall cavity quietly cultivating a microbial ecosystem behind your headboard for three years.

Move or remediate?

We’ll be straight with you about what we see. Statistically, in our practice, the patients who move tend to get better. Remediation absolutely can work and can help a great deal — but we have also watched many remediations fail, sometimes expensively, because the underlying moisture problem or a hidden reservoir was never truly resolved. We don’t say this to frighten anyone; we say it so you go in with clear eyes. When remediation is the right call, we have a vetted team of assessors and remediators we trust and can refer you to.

Why a spore-trap test isn’t enough

The cheap air-sampling “spore trap” that many inspectors lead with captures a single moment in time and misses far too much. It tells you little about Actinobacteria, nothing about endotoxin, and can read “normal” in a home that is clearly making someone sick. We go deeper into this in our article on the inadequacy of spore-trap testing. We strongly recommend an ERMI dust test, which samples settled dust for a far more representative picture of what’s actually accumulating in the home. And if you have neurological symptoms — brain fog, fatigue, cognitive decline — we strongly recommend adding the Actinobacteria and endotoxin testing, because those are so often the hidden drivers of exactly those symptoms. That combination corresponds to EnviroBiomics Panel #8.

For confirming whether a home is safe to re-occupy after remediation, the HERTSMI-2 score is the practical yardstick — a weighted score built from the most CIRS-relevant mold species:

Air filtration & humidity

While you work on the source, you also want to lower the airborne load and keep humidity under 50%. For air purification we recommend iAdaptAir or Air Oasis units — the bipolar-ionization-style purifiers many sensitive patients tolerate and benefit from. (A note for the very sensitive: some people react at first as the unit decontaminates the air; that initial response often settles.)

Getting a real mold inspection

An advanced inspection is absolutely critical — and most aren’t advanced. We recommend only a couple of inspectors in the Atlanta area whom we’ve found genuinely adequate (same with remediators); please reach out for a referral. At minimum, a competent CIRS-literate inspector should understand and test for ERMI dust analysis (not just spore traps), what makes a building safe for a biotoxin-susceptible person, Actinobacteria, endotoxins, and VOCs. And they must be willing to look where the problems actually hide: inside wall cavities, the roof, and every HVAC coil, using thermal imaging to find concealed moisture. Without that, it’s entirely possible to walk away believing your home is fine when it is the very thing keeping you sick.

When you’ve left the moldy home and still have CIRS

Some patients do everything right — they leave, they remediate, they test clean — and the inflammatory machinery still won’t switch off. The illness has, in effect, become self-sustaining. For these cases we use targeted accelerators to help break the cycle and speed recovery:

• Hyperbaric Oxygen Therapy (HBOT) — pressurized oxygen to support oxygen-dependent detoxification, reduce inflammation, and aid tissue repair.
• EBOO ozone therapy — advanced whole-blood ozonation/filtration to lower inflammatory and microbial burden and improve resilience.
• TruDose PRP — regenerative platelet-rich plasma to help recalibrate immune signaling and support repair. We are the only TruDose PRP provider in Georgia.

These are powerful tools — but they are accelerators, not magic. Nothing holds if you’re still getting ongoing exposure or periodic “mold hits.” The environment always comes first.

The Tree of Light approach to CIRS+

With a complex patient, sequence is everything. Treating the right thing in the wrong order is one of the fastest ways to trigger a flare and erode trust. Our general order of operations — always individualized — looks like this:

1. Stabilize and assess. Map the full picture with history, labs, genomics where appropriate, NeuroQuant where indicated, and ART. Rule out the mimics — sleep apnea, metabolic disease, parasites — and identify the real drivers.
2. Remove exposure. No protocol holds in an unsafe environment. The building comes first.
3. Open drainage and steady the terrain. Bowels, bile, lymph, hydration, minerals, mast-cell stability, and nervous-system regulation — built before heavy detox, not after.
4. Bind and lower biotoxin burden. The Shoemaker backbone, titrated to the patient’s true tolerance, with cholestyramine and/or better-tolerated colesevelam plus natural binders.
5. Win the sinus battle. Clear MARCoNS and rebalance the sinus biome; pass VCS before advancing.
6. Address infections in a tolerated sequence. Often viral first (usually well tolerated), then Actinobacteria as a middle step, then parasites and gut, then Lyme and co-infections, and finally biofilms — at the intensity the body will accept, which may be a fraction of a “textbook” dose at first.
7. Resolve interference fields. Coordinate with biological dentistry for cavitations and failing root canals when they’re blocking progress.
8. Repair and re-regulate. VIP, brain-volume support (including plasmalogen/lipid strategies), hormone balance, mitochondrial and peptide support, and continued nervous-system work to restore resilience and guard against relapse.

To carry that out, we draw on the full toolkit in our office — chosen selectively and intentionally, never all at once:

• Diagnostic & guidance: ART, OligoScan, genomic and biotoxin lab interpretation, NeuroQuant referral, advanced sinus-biome testing.
• Detox & oxidative support: EBOO ozone therapy, HBOT, IV nutrient and binder protocols, Field Control Therapy (FCT) for deep reservoirs too aggressive for standard detox.
• Nervous system & immune regulation: IASIS microcurrent neurofeedback, neural therapy, Low-Dose Immunotherapy (LDI), peptide and bioidentical hormone therapy, TruDose PRP.
• Coordination: referral to trusted biological dentists and vetted environmental professionals when the terrain demands it.

What recovery actually looks like

Here is the genuinely hopeful part. The field now uses the word “cure” — cautiously, and never as a guarantee — because clinicians are seeing a steady stream of complex patients return to normal function. The transcriptomic research even shows grey-matter volume recovering with treatment, and in our own practice we’ve watched patients who were nonfunctional travel, work, and live fully again. Recovery from CIRS+ is rarely linear, and it asks for patience from both patient and provider. But with the environment controlled, drainage open, the nervous system calmed, the sinuses cleared, biotoxins lowered, and the hidden infections addressed in the right order, people who were told their labs were “normal” while their lives fell apart genuinely get their lives back. We see it.

One last piece, easy to overlook: recovery isn’t only physiological. As the burden lifts, it matters enormously to re-enter your life on purpose — to gently add back the experiences, relationships, and activities the illness took. Healing the body opens the door; walking back through it is its own, equally important work.

Keep reading — our companion guides